NBIX - ニュ―ロクライン・バイオサイエンシズ （Neurocrine Biosciences Inc.）

Mercer Global Advisors Inc. ADV lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 9.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,086 shares of the company’s stock after buying an additional 259 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Neurocrine Biosciences were worth $369,000 […]

Neurocrine Biosciences shows promising growth, boosted by Ingrezza sales, but struggles with high operational costs. Find out why NBIX stock is a Hold.

Neurocrine Biosciences (NBIX) noted that its supplemental New Drug Application for valbenazine as a treatmetn for chorea associated with Huntington''s disease has an Aug

- Statistically Significant Improvement in Chorea Associated with Huntington''s Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically Significant Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response…

- Statistically Significant Improvement in Chorea Associated with Huntington''s Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically Significant Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response Status

The following slide deck was published by Neurocrine Biosciences, Inc.

The Congenital Adrenal Hyperplasia market is expected to surge due to the disease''s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Adrenal Hyperplasia pipeline products will significantly revolutionize the Congenital Adrenal Hyperplasia market dynamics.

Start Time: 08:00 January 1, 0000 9:02 AM ETNeurocrine Biosciences, Inc.

Neurocrine Biosciences reported strong fourth-quarter profit growth on Monday and beat fourth-quarter estimates. But NBIX stock was flat.

Companies Reporting Before The Bell • Cummins (NYSE: CMI ) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. • ON Semiconductor (NASDAQ: ON ) is expected to report quarterly earnings at $1.27 per share on revenue of $2.08 billion. • Neurocrine Biosciences (NASDAQ: NBIX ) is likely to report quarterly earnings at $1.14 per share on revenue of $409.09 million. • Affiliated Managers Group (NYSE: AMG ) is projected to report quarterly earnings at $7.06 per share on revenue of $589.28 million. • Tyson Foods (NYSE: TSN ) is expected to report quarterly earnings at $1.36 per share on revenue of $13.52 billion. • Energizer Hldgs (NYSE: ENR ) is estimated to report quarterly earnings at $0.76 per share on revenue of $785.86 million. • IDEXX Laboratories (NASDAQ: IDXX ) is projected to report quarterly earnings at $1.94 per share on revenue of $820.91 million. • CNA Financial (NYSE: CNA ) is estimated to report quarterly earnings at $0.97 per share on revenue of $2.28 billion. • NAPCO Security Techs (NASDAQ: NSSC ) is expected to report quarterly earnings at $0.14 per share on revenue of $39.14 million. • Daseke (NASDAQ: DSKE ) is estimated to report quarterly earnings at $0.06 per share on revenue of $397.07 million. • Loews (NYSE: L ) is projected to report earnings for its fourth quarter. • Alico (NASDAQ: ALCO ) is likely to report quarterly loss at $0.31 per share on revenue of $8.10 million. • Graham (NYSE: GHM ) is estimated to report quarterly loss at $0.10 per share on revenue of $30.00 million. • Timken (NYSE: TKR ) is expected to report quarterly earnings at $1.09 per share on revenue of $1.09 billion. • ORIX (NYSE: IX ) is estimated to report earnings for its third quarter. • Mesa Laboratories (NASDAQ: MLAB ) is likely to report quarterly earnings at $0.14 per share on revenue of $57.74 million.

Neurocrine is acquiring beaten-down Diurnal Group for $57M to accelerate its ex-U.S. business development. Find out what this means for investors in NBIX stock.

The shares of U.K.-based biotech Diurnal rose in London in the morning hours Tuesday after the company announced a deal to be acquired by San Diego, California-based Neurocrine…

Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%.

Neurocrine Biosciences (NBIX) stock rose ~8% on Aug

Tucked in its Q2 earning release , Neurocrine Biosciences Inc (NASDAQ: NBIX ) said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints. Based on the totality of data from the Phase 2a study, at this time, the company will not proceed further with the clinical development of NBI-827104 in essential tremors. The Full story available on Benzinga.com